Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells
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An Open Access Publisher 5-Aza-2'deoxycytidine (5-Aza-CdR/decitabine) [11, 12] . The action of 5-Aza-CdR results from its incorporation into DNA, resulting in the loss of DNA methylation by irreversibly trapping the DNA methyltransferase 1 (DNMT1) to DNA [13] .
The potential clinical importance of inhibitors of DNMT1 in lung cancer is supported by some interesting responses observed in some NSCLC patients treated with 5-Aza-CdR alone or 5-azacytidine in combination with an inhibitor of histone deacetylase (HDACs) [14, 15] . These reports provide a rationale to search for other agents to use with 5-AzaCdR to increase its efficacy for the treatment of NSCLC. Another interesting aspect of DNA methylation inhibitors is their "epigenetic priming", which can make tumors more sensitive to subsequent treatment with cytotoxic drugs [16, 17] .
A second epigenetic pathway that has been shown to be dysregulated in cancer is gene silencing mediated by the polycomb repressor complex 2 (PRC2) [18, 19] . EZH2 (enhancer of zeste homolog 2), the catalytic subunit of PRC2, is a histone methyltransferase that trimethylates lysine 27 in histone H3 (H3K27me3), an epigenetic marker that silences gene expression. Deregulation of EZH2 is proposed to occur during malignant transformation in different types of cancer [20] [21] [22] . EZH2 is frequently overexpressed in NSCLC and is correlated with poor prognosis [23] . These observations suggest that EZH2 is an interesting target for chemotherapy of lung cancer.
3-Deazaneplanocin-A (DZNep) is a S-adenosylhomocysteine hydrolase inhibitor that inhibits EZH2 activity and induces apoptosis in different types of cancer cells [24] [25] [26] . DZNep also shows significant antineoplastic activity against NSCLC cells [27] . Other agents have been developed that also target EZH2. U-4149 is an analogue of DZNep with a similar mechanism of action. Gsk-126 is a specific inhibitor of EZH2 and currently is clinical trial in patients with lymphoma (ClinicalTrials.gov identifier: NCT02082977).
The aim of our investigation was to compare the in vitro antineoplastic activity of DZNep, U-4149 and Gsk-126 on human A549 lung carcinoma cells. Previous studies in our laboratory have shown that 5-Aza-CdR in combination with DZNep exhibits synergistic antineoplastic action on leukemic cells [28] . Our second aim was to investigate the relative antineoplastic activity of the different agents that target EZH2 in combination with 5-Aza-CdR against the lung carcinoma cells.
Materials and methods
Cell lines and materials
Human non-small cell lung cancer cell line A549 (adenocarcinoma) was purchased from American Type Culture Collection (ATCC). A549 was cultured in -MEM medium (Invitrogen) with 10% fetal bovine serum (FBS) and maintained in a 37C incubator with 5% CO 2 . 5-AzaCdR was obtained from the Institute of Organic Chemistry (Prague, Czech Republic,). DZNep (3-deazaplanocin-A) was kindly provided by Dr Victor E. Marquez, Chemical Biology Laboratory (Frederick, MD). The chemical synthesis of U-4149, fluoro analogue of DZNep, was performed using the method of Choi et al. [29] . 5-Aza-CdR, DZNep and U-4149 were dissolved in sterile phosphate buffer saline pH 6.8 (PBS) solution. Gsk-126 was obtained from Xcess Biosciences Inc. and was dissolved in DMSO. High Capacity cDNA Reverse Transcription Kit, random primers and universal PCR mixture were obtained from Applied Biosystems and RNeasy plus mini kit from Quiagen. Senescence staining kit was obtained from Sigma-Aldrich and CellEventR Caspase 3/7 Green Detection Reagent was obtained from Life technologies.
Clonogenic assays
The exponentially growing A549 lung carcinoma cells were trypsinized into a single cell suspension. Two hundred fifty cells were seeded in 6-well (9.6 cm 2 /well) plates containing -MEM with 10% FBS. The next day the cells were treated with different concentrations of DZNep, Gsk-126 and U-4149 for 6, 12, 24, 48 and 72 h using a time-and dose-response studies. At the end of treatment, the cells were suspended in drug-free medium and maintained in a 37C incubator with 5% CO 2 . The number of colonies after staining with Giemsa/methanol was counted after 16-18 days of incubation and the loss of clonogenicity was determined. For sequential treatment in the drug combination assay, A549 cells were treated with 0.1 M 5-Aza-CdR. At 24 h either 1 M DZNep, 2.5 M Gsk-126 or 1 M U-4149 were added to the medium. The cloning efficiency was in the range of 60-70%. All the experiments were performed in triplicate. Similar conditions were used for the growth inhibition assay, except at each time point, the medium was aspirated and the cells trypsinized for a cell count using the Beckmann Model Z Coulter.
Senescence-associated--galactosidase (SA--Gal) staining
The senescence staining kit was used to identify senescent cells at the end of drug treatment. Twenty thousand cells were plated in 6-well plates and allowed to adhere to the surface in a 37C with 5% CO 2 the day before of drug treatments. Treatments were made as described for the clonogenic assays. At 24 h after the end of drug treatment, the medium was aspirated and the cells were washed twice with PBS followed by incubation at room temperature with fixation buffer. The cells were rinsed with PBS and the staining mixture was added. The plate was incubated overnight at 37C without CO 2 . The blue-stained cells (senescent) and the total number of cells were counted using a microscope. The percentage of senescent cells was compared to total number of cells.
Apoptosis-associated-Caspases
The CellEventR Caspase-3/7 Green reagent was used to detect caspases 3 and 7 in A549 tumor cells at the end of drug treatment. Ten thousand cells were seeded on glass coverslips and allowed to adhere to the surface in a 37C incubator with 5% CO 2 the day before of drug treatments. Treatments proceeded as described for clonogenic assays. At 24 h after the end of drug treatment, the probe solution was added to the cells. The glass coverslips was incubated for 30 min in the dark at room temperature. Then, stained cells were observed under fluorescence microscopy.
Analysis of gene expression
For gene expression analysis, the cell treatments were performed as described in clonogenic assay. At the end of drug treatment, the cells were centrifuged, suspended in drug-free medium and counted. Total RNA purification was carried out following the manufacturer's instructions of the RNeasy plus mini kit. For cDNA preparation, 2 g of total RNA was reversed transcribed using the cDNA Reverse Transcription Kit with random primers as described by the manufacture. The reaction mixture contained cDNA, specific primers for the target genes (CDKN1A (p21), RUNX3 and RASSF1), Sybr green and TaqMan Fast Universal PCR Master Mix. The ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used to detect the amplification level. All reactions were run in triplicate and the average Cts were used for quantitation. The endogenous controls were TATA-binding protein (TBP) gene and hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene. The relative quantification of the target genes was determined using the CT method. Briefly, the Ct (threshold cycle) values of the target gene were normalized to the endogenous control TPB and HPRT genes (CT  Cttarget −Ctcontrol) and compared with a calibrator: CT  Ctsample − Ctcalibrator. Relative expression (RQ) was calculated using the Sequence Detection System (SDS) 2.2.2 software (Applied Biosystems) and the formula: RQ  2−CT. The sequences of the primers used in the study were CDKN1A (Forward: tcactgtcttgtacccttgtgc and Reverse: ggcgtttggagtggtagaaa), RUNX3 (Forward: tcagcaccacaagccactt and Reverse: aatgggttcagttccgaggt) and RASSF1A (Forward: gactctggggaggtgaactg and Reverse: ggagtacttctgcaggatctgg).
Statistical analysis
The data are expressed as means  standard error of mean (SEM). Statistical analyses were performed using one-way analysis of variance (ANOVA) and Student's t-test to evaluate differences between groups. P  0.05 was considered statistically significant. ( 30%) and at 2.5 M ( 40%) (Figure 2a ). For a 24 h exposure, 1 M Gsk-126 showed the lowest antineoplastic effect against A549 tumor cells as compared to the other EZH2 inhibitors, showing a loss of clonogenicity (20%) and at 2.5 M ( 30%) (Figure 2b ). The cells were more sensitive to 1 M U-4149 after 24 h exposure, as shown by a loss of clonogenicity ( 40%) and at 2.5 M ( 55%) (Figure 2c ). DZNep and Gsk-126 required either higher concentration or a longer exposure drugs to produce a loss of clonogenicity  40% on A549 tumor cells. 
Results
Evaluation of the antineoplastic activity of DZNep, Gsk-126 and U-4149 on A549 lung tumor cells
Loss of clonogenicity of A549 lung tumor cells by combination of epigenetic agents
A colony assay was performed to determine the loss of clonogenicity of A549 cells produced by each individual epigenetic agent (5-Aza-CdR, DZNep, Gsk-126 and U-4149) and the different double combinations of these agents. We used a sequential drug treatment that started with 5-AzaCdR and was followed by the addition of the EZH2 inhibitors at 24 h. The drugs were removed at 48 h and replaced with drug-free medium. Single agent's treatments showed the loss of clonogenicity of: 20% (5-Aza-CdR), 29% (DZNep), 36% (Gsk-126) and 41% (U-4149) for a 24 h exposure of A549 tumor cells (Figure 3a) . The double combinations exhibited a significantly greater loss of clonogenicity than the single agents. The double combination 5-Aza-CdR plus DZNep showed remarkable antineoplastic activity as indicated by 53% loss of clonogenicity. 5-Aza-CdR plus Gsk-126 showed 54% loss of clonogenicity and 5-Aza-CdR plus U-4149 showed 64% loss of clonogenicity (Figure 3a) . All the double combinations showed a synergistic effect against A549 tumor cells. The most synergistic effect was observed with 5-Aza-CdR plus U-4149. When the concentration of 5-Aza-CdR was increased from 0.1 M to 0.2 M, all the double combinations showed a greater synergistic effect against A549 tumor cells (Figure 3b) . The most synergistic effect was 5-Aza-CdR plus U4149 ( 84%) for both concentrations of 5-Aza-CdR (0.1 or 0.2 M). In conclusion, we observed that the inhibitors of EZH2, DZNep, Gsk-126 and U-4149, enhanced the action of 5-Aza-CdR on lung A549 lung tumor cells and U-4149 was more potent than DZNep or Gsk-126.
Growth inhibition assay
The growth inhibition of A549 tumor cells was determined by cell counting at the end of drug treatment. Single agent treatment showed a growth inhibition of 33 to 35%, except for 2.5 M Gsk-126, which showed only 14% growth inhibition (Table 1 ). All the double combinations were observed a significantly greater growth inhibition than the single agents for a total 48 h drug treatment (Table1).
Senescence analysis
For identifying senescent cells, we used an assay based on a histochemical stain for -galactosidase activity. At pH 6 this enzyme is detectable in senescent cells. Phase contrast images of A549 tumor cells after 2 days of drug treatment showed reduced cell numbers, damaged cells, and some normal-looking cells (Figure 4) . A small number Table 1 Growth inhibition assay of A549 cells after treatment with 5-AzaCdR (A), DZNep (D), Gsk-126 (G) and U-4149 (U). 
Drug concentration Growth inhibition (%)
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Apoptosis analysis
We investigated the induction of apoptosis by 5-Aza-CdR, DZNep, Gsk-126 and U-4149 and their combinations with 5-Aza-CdR using a caspase green detection reagent, which becomes fluorescent upon cleavage by active caspases 3 and 7. Our results show that these epigenetic agents induce apoptosis in A549 tumor cells and that caspases are involved in this event ( Figure 5 ). All the combinations showed a greater number of apoptotic cells as compared to the respective single agents.
Analysis of gene expression
In order to understand if the antineoplastic action of these epigenetic agents correlated with the activation of genes that are frequently silenced in NSCLC, we analyzed the expression of three TSGs genes: CDKN1A (p21), RUNX3 and RASSF1. The analysis of mRNA levels of these genes of senescent cells were identified in the untreated cells (7%) or the cells treated with 5-Aza-CdR alone (9.5%). The cells treated with DZNep, Gsk-126 and U-4149 showed 12%, 9% and 16% of senescent cells, respectively. A synergistic interaction was observed for all combinations as shown by the increase in the number of senescent cells. The highest number of senescent cells was observed in 5-Aza-CdR plus U-4149 group (100%), followed by 5-Aza-CdR plus DZNep (24%) and 5-Aza-CdR plus Gsk-126 (13%). All the double combinations showed damaged cells, senescent cells and some healthy-looking cells, except for 5-Aza-CdR plus U-4149 treatment, where no healthy-looking cells were observed. The data are in accord with loss of clonogenicity and growth inhibition analysis.
Discussion
Aberrant DNA methylation was shown to be a key epigenetic modification of TSGs in NSCLC [30] making it an attractive target in cancer therapeutics. Inhibition of DNMT1 is currently being investigated for the therapy of NSCLC (ClinicalTrials.gov Identifier: NCT01935947). A phase I-II clinical trial on 5-Aza-CdR was performed at our University medical center in patients with stage IV metastatic NSCLC [14] . This pilot study showed some promising activity, including one patient that survived 7 years. The therapeutic effectiveness of 5-Aza-CdR against cancer may be limited by the fact that it only reactivates 30-40% of the genes silenced by DNA methylation [31] . In addition, 5-Aza-CdR has difficulty to activate DNA methylated genes if they contain the histone gene-silencing marker, H3K27me3 [18, 19] .
In the present work, we demonstrate that it is possible to increase the effectiveness of 5-Aza-CdR against lung cancer by using it in combination with other epigenetic agents.
We selected drugs that target directly or indirectly EZH2, a subunit of PRC2 that is responsible for the methylation of H3K27 to silence gene expression. The agents we selected were global histone methylation inhibitors, DZNep and its related analogue, U-4149, and the specific EZH2 inhibitor Gsk-126. All these histone methylation inhibitors when used in combination with 5-Aza-CdR showed a synergistic effect against A549 lung carcinoma cells. U-4149 was showed to be more potent than DZNep or Gsk-126 as a single agent and in combination with 5-Aza-CdR.
DZNep is a derivative of the antibiotic neplanocin-A. DZNep is not a direct EZH2 inhibitor, but rather a SAH-hydrolase inhibitor. Inhibition of this enzyme leads to an increase of the intracellular SAH concentration and reduction in the level of S-adenosylmethionine, which results in the Table 1 . At 48 h the drugs were removed and at 72 h RNA was isolated for RT-PCR analysis as described in Methods. The relative gene expression is shown as mean  SEM, n  3. Statistical analysis was made by one way ANOVA;  (P  0.05)
Note: Wording within each graph very difficult to read. If possible should be enlargened.
inhibition of EZH2 [19] . DZNep was able to reactivate EZH2 target genes and induced apoptosis in different types of cancer cells [25, 26, 32] . DZNep, as a single agent, also showed a significant antineoplastic activity against NSCLC cells [27] . We reported previously that 5-Aza-CdR plus DZNep exhibited a synergistic interaction against leukemic cells [28] . In the present work, our data show that this combination is also synergistic against A549 NSCLC cells. Our results also indicate that epigenetic therapy that specifically targets both DNMT and EZH2 is very effective.
The combination of U-4149 plus 5-Aza-CdR was more potent for treatment of NSCLC than the combinations containing either DZNep or Gsk-126. U-4149 is the fluoroadenosine analogue of DZNep.
Previous studies have indicated that methylation of specific genes resulting in epigenetic silencing occurs in lung cancer [9] . Inactivation of these genes favors tumorigenesis by suppressing differentiation, apoptosis and senescence. Cellular senescence is a tumor-suppressive mechanism that permanently prevents cells from malignant transformation [33] . We investigated the induction of senescence by these epigenetic agents by evaluation of inhibition of cell growth and induction of -galactosidase expression. All the double combinations showed induction of senescence in A549 tumor cells. The combination 5-AzaCdR plus U-4149 exhibited the highest level of senescence as compared with the other combinations.
The induction of apoptosis is an important action of many anticancer agents. Caspases play an important role in the regulation and execution of apoptotic cell death [34] . We reported previously that 5-Aza-CdR in combination with DZNep induces a synergistic induction of apoptosis in leukemia cells [35] . We observed that the combination of these epigenetic agents also induce apoptosis in lung carcinoma cells.
was made by real-time RT-PCR. Each agent alone produced a small increase in expression of these genes that was less than some double combinations. 5-Aza-CdR plus DZNep produced an activation of p21 by 2.0 fold and RUNX3 by  1.8 fold relative to control cells. This combination did not show a significant activation of RASSF1 (P  0.05) ( Figure  6a ). 5-Aza-CdR plus Gsk-126 produced an activation of CDKN1A by  2.5 fold and RUNX3 by  1.6 fold, but no significant change in the expression of RASSF1 (Figure 6b ). 5-Aza-CdR plus U-4149 produced an activation of CDKN1A by  3.2 fold and RASSF1 by  2.5 fold, but not RUNX3 as compared to the control cells (Figure 6c ). The activation of CDKN1A and RASSF1 by 5-Aza-CdR plus U-4149 was greater than the other combinations. The silencing of the expression TSGs by DNA and histone methylation can play a crucial role in malignant transformation to NSCLC [9] . In order to determine if this epigenetic gene-silencing mechanism is reversible, we treated A549 tumor cells with 5-Aza-CdR, DZNep, Gsk-126 and U-4149 and analyzed the expression of three TSGs: CDKN1A (p21), RUNX3 and RASSF1. These genes can play an important role in the regulation of cell growth of NSCLC.
CDKN1A (p21) is a cyclin-dependent kinase inhibitor that is correlated with cell-cycle arrest that precedes terminal differentiation in a variety of tissues. In response to DNA damage, p53 induces CDKN1A expression, which induces cell cycle arrest at the G1 checkpoint [36] . Aberrant DNA methylation of CDKN1A has been observed in various malignancies, including lung cancer [37] . Zheng et al demonstrated that treatment with DNMT1 inhibitors enhanced CDKN1A levels [38] . In our study, all the three combinations of inhibitors of DNA and histone methylation exhibited a synergistic activation of CDKN1A.
RUNX3 is a downstream effector of the TGF- signaling pathway, and has critical roles in the regulation of cell death by apoptosis [39] . RUNX3 is frequently silenced by DNA hyper-methylation in many cancers, including lung cancer [39] [40] [41] . RUNX3 methylation correlates with clinical stage and degree of differentiation in NSCLC [42] . In our study the combinations of 5-Aza-CdR plus DZNep and 5-Aza-CdR plus Gsk-126 exhibited a synergistic activation of RUNX3. These results showing an increase of the expression of RUNX3 by these epigenetic agents are in accord with their increase induction of apoptosis.
RASSF1A shows a high frequency of decreased expression and increased promoter methylation in NSCLC [43] . RASSF1A methylation was associated with poor prognosis in NSCLC patients [44, 45] . In our study only the combination of 5-Aza-CdR plus U-4149 showed a synergistic activation of RASSF1.
Conclusion
Our results suggest that a combination of inhibitors of DNA and histone methylation have interesting potential for the therapy of lung cancer. Additional studies on the in vivo activity of these combinations in animal tumor models of lung cancer will be helpful in the selection of the combination that may have the greatest potential for effective clinical treatment of lung cancer.
